Investment

A UK centre for synthetic biology has received £5.5 million in funding so it can support start-ups and SMEs in the sector.  The UK’s National Centre for the Industrial Translation of Synthetic Biology, SynbiCITE, will use the funding to support businesses within the sector and to help strengthen the emerging UK bioeconomy. The centre was […]

Origin Therapeutics, an investment company focused on psychedelic therapies, has added Canadian biotech Clairvoyant to its portfolio.  Clairvoyant is developing psychedelic drug therapy focused on addiction and is targeting the clinical validation of psilocybin in the EU, the UK, and Canada. The company is currently proceeding with a Phase II clinical trial in Canada for […]

A University of Cambridge spin-out has secured £2.4 million of investment to help it develop a pipeline of antibody drug conjugate (ADC) therapies for solid tumours.  Spirea is developing ACD therapeutics for solids tumours with a high unmet need. The company has developed technology that enables more cytotoxic drug to be attached to the targeting […]

uMotif today announced a new investment of $25.5 million from a fund managed by Athyrium Capital Management, LP, the New York-based investment firm. The new funding will support continued scale up of uMotif’s unique patient-first software platform for clinical research.  The company’s software is designed to provide pharmaceutical, biotech, medtech and Contract Research Organisation (CRO) […]

News round-up by DDW’s Reece Armstrong for 23-27 May   UK investment plans, company appointments to drive strategy, and digital health platforms are some of the themes of this week’s news round-up.    New £20m fund launches to support North West life sciences  A new £20 million fund has been launched in the Northwest of England to […]

A new £20 million fund has been launched in the Northwest of England to help support the region’s life sciences sector. The ‘GMC Life Sciences Fund By Praetura’ is a partnership between Greater Manchester Combined Authority (GMCA), Cheshire and Warrington Local Enterprise Partnership (LEP), Bruntwood SciTech and Praetura Ventures. It combines capital, expertise and resources […]

Clinical-stage biotech Redx has raised £34 million in funding to help it progress its pipeline of therapeutics targeting cancer and fibrotic disease.   Redx raised the funding through a Bookbuild process in which a company generates investor demand when raising capital in an attempt to achieve the best price for selling shares.   As such, Redx placed […]

The LSX World Congress returned for an in-person event in May, bringing together executives from the biotech, medtech and healthtech sectors, across two days to examine the latest trends across life sciences.  DDW’s Reece Armstrong attended the event – here are the key takeaways from the show.  One of the key theme’s across LSX was […]

Switzerland’s life sciences sector saw a strong year in 2021 with companies contributing to the Covid-19 pandemic and high levels of capital investments being key indicators of the sector’s strength.   This is according to the latest edition of the Swiss Biotech Report1 which was launched by the Swiss Biotech Association.   The sector saw a strong […]

BioXcel Therapeutics has raised $260 million in funding to support the commercial activities of its proprietary, orally dissolving film formulation IGALMI. Previously known as BXCL501, IGALMI is an orally dissolving film formulation of dexmedetomidine indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The funding comes […]